Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Granulocyte colony-stimulating factors; Nivolumab; Vinblastine
Indications Hodgkin's disease
Focus Adverse reactions; Therapeutic Use
Sponsors Seagen

10 Dec 2024 Results (n=154, at the data cutoff of May 30, 2024) updated results of part C enrolled patients with Ann Arbor stage I or II cHL without bulky disease with long term follow up, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
05 Dec 2024 According to a Pfizer media release, data from this trial to be presented at American Society of Hematology (ASH) Annual Meeting & Exposition (December 7-10) and the San Antonio Breast Cancer Symposium (SABCS, December 10-13).
07 Oct 2024 Status changed from active, no longer recruiting to discontinued.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com